| 65 | 1 | 23 |
| 下载次数 | 被引频次 | 阅读次数 |
为了评估加速超分割根治性放疗对中央型小肺肿瘤的治疗疗效和毒性,本研究将在本院接受加速超分割根治性放疗治疗的50例中央型小肺肿瘤患者作为研究对象,术后随访至2017年1月,考察患者的疗效、总生存率、局部控制率和毒性。参加研究的27名男性和23名女性的平均年龄为78.4岁(范围:61～86岁)。肿瘤分期:T1a 12例、T1b 21例、T2a 17例,肿瘤直径总中位大小26.3 cm (12～48 cm)。组织学类型为腺癌25例,鳞状细胞癌15例,其他2例,临床诊断未知8例。分别有4例完全缓解(8.0%),21例部分缓解(42.0%),总有效率为50%。2年、3年和5年的局部控制率分别为86.0%、82.0%和80.0%,总生存率分别为80.0%、68.0%和54.0%。5例(10%)发生3级肺炎,未观察到其他严重不良事件(≥3级)。初步的结论表明,对于中央型小肺癌患者,加速超分割根治性放疗是一种比常规放疗更有效的治疗方法。
Abstract：To assess the therapeutic efficacy and toxicity of accelerated hypofractionated radical radiotherapy in the treatment of central type small lung tumors. 50 patients with central type small lung tumors who underwent accelerated hypofractionated radical radiotherapy in our hospital from March 2008 to January 2012, were as the subjects and followed up until January 2017. The curative effect, overall survival rate, local control rate and toxicity were studied in this research. The average age of the 27 men and 23 women participating in the study was 78.4 years(range: 61～86 years). There were 12 cases of T1 a stage, 21 cases of T1 b stage and 17 cases of T2 a stage. The total tumor size was 26.3 cm(12～48 cm). Histological types of adenocarcinoma in 25 cases, squamous cell carcinoma in15 cases, the other 2 cases, 8 cases of unknown clinical diagnosis. There were 4 cases of complete remission(8.0%),21 cases of partial remission(42.0%), the total effective rate was 50%. The two-year, three-year and five-year local control rates were 86.0%, 82.0% and 80.0%, respectively. The overall survival rates were 80.0%, 68.0% and 54.0%,respectively. Grade 3 pneumonia occurred in 5 patients(10%) and no other serious adverse events(≥3) were observed. Preliminary results suggest that accelerated hyperfractionated radical radiotherapy is a more effective treatment than conventional radiotherapy for patients with central type small lung tumors.
Ba schnagel A.M.,Mangona V.S.,Robertson J.M.,Welsh R.J.,Kestin L.L.,and Grills I.S.,2013,Lung metastases treated with image-guided stereotactic body radiation therapy,Clin.Oncol.,25(4):236-241
Brahmer J.,Reckamp K.L.,Baas P.,CrinòL.,Eberhardt W.E.,Poddubskaya E.,Antonia S.,Pluzanski A.,Vokes E.E.,Holgado E.,Waterhouse D.,Ready N.,Gainor J.,Arén Frontera O.,Havel L.,Steins M.,Garassino M.C.,Aerts J.G.,Domine M.,Paz-Ares L.,Reck M.,Baudelet C.,Harbison C.T.,Lestini B.,and Spigel D.R.,2015,Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer,New England J.Med.,373(17):123-135
Hirsch F.R.,Varella-Garcia M.,Jr B.P.,Franklin W.A.,Dziadziuszko R.,Thatcher N.,Chang A.,Parikh P.,Pereira J.R.,Ciuleanu T.,von Pawel J.,Watkins C.,Flannery A.,Ellison G.,Donald E.,Knight L.,Parums D.,Botwood N.,and Holloway B.,2006,Molecular predictors of outcome with gefi tinib in a phaseⅢplacebo-controlled study in advanced non-small-cell lung cancer,J.Clin.Oncol.,24(31):5034-5042
Inoue A.,Kobayashi K.,Usui K.,Maemondo M.,Okinaga S.,Mikami I.,Ando M.,Yamazaki K.,Saijo Y.,Gemma A.,Miyazawa H.,Tanaka T.,Ikebuchi K.,Nukiwa T.,Morita S.,Hagiwara K.,and North East Japan Gefitinib Study Group,2009,First-line gefitinib for patients with advanced nonsmall-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy,J.Clin.Oncol.,27(9):1394-1400
Nagata Y.,Hiraoka M.,Mizowaki T.,Narita Y.,Matsuo Y.,Norihisa Y.,Onishi H.,and Shirato H.,2009,Survey of stereotactic body radiation therapy in Japan by the Japan3-D conformal external beam radiotherapy group,Int.J.Rad.Oncol.Biol.Physics,75(2):343-347
Nagata Y.,Takayama K.,Matsuo Y.,Norihisa Y.,Mizowaki T.,Sakamoto T.,Sakamoto M.,Mitsumori M.,Shibuya K.,Araki N.,Yano S.,and Hiraoka M.,2005,Clinical outcomes of a phaseⅠ/Ⅱstudy of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame,Int.J.Rad.Oncol.Biol.Physics,63(5):1427-1431
Onishi H.,Araki T.,Shirato H.,Nagata Y.,Hiraoka M.,Gomi K.,Yamashita T.,Niibe Y.,Karasawa K.,Hayakawa K.,Takai Y.,Kimura T.,Hirokawa Y.,Takeda A.,Ouchi A.,Hareyama M.,Kokubo M.,Hara R.,Itami J.,and Yamada K.,2004,Stereotactic hypofractionated high-dose irradiation for stageⅠnonsmall cell lung carcinoma:clinical outcomes in245 subjects in a Japanese multiinstitutional study,Cancer,101(7):1623-1631
Qiao X.,Tullgren O.,Lax I.,and Lewensohn R.,2003,The role of radiotherapy in treatment of stageⅠnon-small cell lung cancer,Lung Cancer,41(1):1-11
Rowe B.P.,Boffa D.J.,Wilson L.D.,Kim A.W.,Detterbeck F.C.,and Decker R.H.,2012,Stereotactic body radiotherapy for central lung tumors,J.Thorac.Oncol.,7(9):1394-1399
Sanchezcespedes M.,Decker P.A.,Doffek K.M.,Esteller M.,Westra W.H.,Alawi E.A.,Herman J.G.,Demeure M.J.,Sidransky D.,and Ahrendt S.A.,2001,Increased loss of chromosome 9p21 but not p16 inactivation in primary non-small cell lung cancer from smokers,Cancer Res.,61(5):2092-2096
Sibley G.S.,1998,Radiotherapy for patients with medically inoperable stageⅠnonsmall cell lung carcinoma:smaller volumes and higher doses-a review,Cancer,82(3):433
Siva S.,Macmanus M.,and Ball D.,2010,Stereotactic radiotherapy for pulmonary oligometastases:a systematic review,J.Thorac.Oncol.,5(7):1091-1099
Soda M.,Choi Y.L.,Enomoto M.,Takada S.,Yamashita Y.,Ishikawa S.,Fujiwara S.,Watanabe H.,Kurashina K.,Hatanaka H.,Bando M.,Ohno S.,Ishikawa Y.,Aburatani H.,Niki T.,Sohara Y.,Sugiyama Y.,and Mano H.,2007,Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer,Nature,448(7153):561-566
基本信息:
DOI：10.13417/j.gab.038.004247
中图分类号:R734.2
引用信息:
[1]赵凌燕.中央型小肺癌治疗中加速超分割放疗的应用[J].基因组学与应用生物学,2019,38(09):4247-4251.DOI:10.13417/j.gab.038.004247.
2019-09-25
2019-09-25